Urigen Pharmaceuticals 305 East High Street Suite 7 Bound Brook, NJ 08805 United States ph: 732-369-5911
Urigen is a privately held company.
If you are a current stock holder in Urigen Pharmaceuticals, please contact the company to obtain a password required to enter the financial information link.
If you have your login information please proceed to the
INVESTOR Secure Portal
Urigen Pharmaceuticals Initiates Multicenter Phase II Trial: “Evaluation of the Safety and Effectiveness of URG101 in Subjects with Interstitial Cystitis/Bladder Pain Syndrome”
Urigen Pharmaceuticals Announces Private Offering to Current Shareholders
CEO Dan Vickery Interviewed about Urigen's clinical program for treating IC/BPS at 2019 Bio CEO Conference
Urigen Series D Financing Investors Qualify for NJ Angel Investor Tax Credit Program